vTv Therapeutics Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.0M | $0 | $2.0M | $4.0M | $6.4M | $2.8M | $12.4M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $17.9M | $11.5M | $13.6M | $12.4M | $13.3M | $11.0M | $15.1M | $23.0M |
| SG&A Expense | $14.9M | $13.7M | $11.9M | $12.2M | $12.3M | $7.3M | $8.5M | $9.2M |
| Operating Income | $-32.8M | $-24.2M | $-25.5M | $-22.5M | $-21.7M | $-11.9M | $-20.9M | $-19.8M |
| Operating Margin | — | -2,377.6% | — | -1,116.9% | -540.9% | -184.8% | -755.9% | -159.4% |
| Interest Expense | — | — | $13.0K | $15.0K | $12.0K | $692.0K | $1.8M | $3.3M |
| Pretax Income | $-31.1M | $-22.6M | $-26.0M | $-24.9M | $-17.6M | $-12.8M | $-21.8M | $-23.6M |
| Income Tax Expense | $0 | $100.0K | $0 | $200.0K | $115.0K | $0 | $100.0K | $200.0K |
| Net Income | $-27.0M | $-18.5M | $-20.3M | $-19.2M | $-13.0M | $-8.5M | $-13.0M | $-7.9M |
| Net Margin | — | -1,815.3% | — | -949.7% | -324.3% | -132.5% | -471.9% | -63.6% |
| EPS (Basic) | — | — | — | — | — | — | — | — |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Diluted) | — | — | — | — | — | — | — | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |